Search clinical trials for: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU

Total 90 results

Topivert Pharma Ltd

Completed

Study of TOP1630 for Dry Eye Syndrome (THEIA-1)

Dry Eye Syndrome

United States
ORA, Inc.
Topivert Pharma Ltd

Completed

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

Dry Eye Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Healthy Subject
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
Rigel Pharmaceuticals

Completed

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca (DROPS)

Keratoconjunctivitis Sicca

United States
Rigel Pharmaceuticals

Completed

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Santen Inc.
ActualEyes Inc.

Active, not recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States, France, India
Allergan

Completed

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma, Open-Angle

United States
Hanlim Pharm. Co., Ltd.

Completed

A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects

Healthy Subjects

France
pH Pharma

Completed

Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

Normal Tension Glaucoma

Korea, Republic of
Allysta Pharmaceutical

Completed

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Yuyu Pharma, Inc.

Active, not recruiting

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Dry Eye

United States
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Aerie Pharmaceuticals

Completed

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Aerie Pharmaceuticals

Completed

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Hoffmann-La Roche

Completed

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-angle

United States
Shenzhen Hospital of Southern Medical University

Unknown

Study on Prevention and Treatment of Dry Eye in Patients Using Glaucoma Drops

Dry Eye | MGD-Meibomian Gland Dysfunction

China
Glaukos Corporation

Withdrawn

Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery

Corneal Ectasia
Laboratorios Sophia S.A de C.V.

Completed

Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. (PRO-037)

Dry Eye

Mexico
Aerie Pharmaceuticals

Completed

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (Rocket-1)

Ocular Hypertension | Open-angle Glaucoma

United States
TetraLogic Pharmaceuticals
PPD; The Leukemia and Lymphoma Society; Veristat, Inc.; Therapeutics, Inc.

Completed

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

Lymphoma, T-Cell, Cutaneous

United States
Eyenovia Inc.

Recruiting

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

Myopia

United States
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Santen Inc.

Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (ANGEL-2)

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Glaukos Corporation

Recruiting

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

United States
Ocuphire Pharma, Inc.

Completed

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Night Vision Complaints | Decrease in Night Vision | Disturbance; Vision, Loss

United States
Ohr Pharmaceutical Inc.

Withdrawn

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Aston University
TearLab Corporation

Completed

Tear Osmolarity Clinical Utility in Dry Eye Disease

Dry Eye

United Kingdom
Region Skane
Vinnova

Completed

PHMB-based Antiseptic Use in Full-thickness Surgical Wounds

Surgical Site Infections

Sweden
University of Pennsylvania
Lions Club International Foundation; Berhan Public Health and Eye Care Consultancy... and other collaborators

Completed

Fluorometholone as Ancillary Therapy for TT Surgery

Trachoma | Trichiasis | Bilamellar Tarsal Rotation

Ethiopia
Skye Bioscience, Inc.

Completed

Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Ohr Pharmaceutical Inc.

Unknown

Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD (MAKO)

Age-related Macular Degeneration

United States
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Allergic Conjunctivitis

Japan
Janssen Research & Development, LLC

Terminated

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Healthy

Belgium
University of Trieste

Completed

PGE2 Levels in Patient Treated With NSAIDs

Ocular Inflammation

Italy
RVL Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

Blepharoptosis

United States
RVL Pharmaceuticals, Inc.

Completed

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Acquired Blepharoptosis

United States
Santen Inc.

Completed

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Healthy

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers

Healthy

Germany
Surface Pharmaceuticals, Inc.

Completed

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Universitat Internacional de Catalunya
Dentaid SL

Completed

Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.

Dental Plaque | Side Effects

Spain
University of Kansas Medical Center

Completed

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

Migraine

United States
Eye & ENT Hospital of Fudan University
Shandong Provincial Hospital; Children's Hospital of Fudan University; Xinhua... and other collaborators

Recruiting

A-eyedrops on Ocular Alignment and Binocular Vision

Myopia | Exotropia | Exophoria

China
Alcon Research

Withdrawn

VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery

Cataracts
Alcon Research

Terminated

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

Corneal Infiltrates

United States
Medical University of South Carolina
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Diabetes Mellitus, Type 1

United States

3

Subscribe